Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

Background The signaling protein p38 mitogen-activated protein kinase (MAPK) regulates the tumor cell microenvironment, modulating cell survival, migration, and invasion. This phase 1 study evaluated the safety of p38 MAPK inhibitor LY3007113 in patients with advanced cancer to establish a recommend...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jonathan W., Rosen, Lee S., Tolcher, Anthony W., Papadopoulos, Kyriakos, Beeram, Muralidhar, Shi, Peipei, Pitou, Celine, Bell, Robert, Kulanthaivel, Palaniappan, Zhang, Xuekui, Fink, Aaron, Chan, Edward M., Shahir, Ashwin, Farrington, Daphne, Patnaik, Amita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061137/
https://www.ncbi.nlm.nih.gov/pubmed/29196957
http://dx.doi.org/10.1007/s10637-017-0532-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061137/
https://www.ncbi.nlm.nih.gov/pubmed/29196957
http://dx.doi.org/10.1007/s10637-017-0532-2

Ejemplares similares